[Clinical studies of T-1982 (cefbuperazone) in pediatric field].
T-1982 (cefbuperazone) is a newly developed cephamycin. Clinical studies on this drug were carried out and the results were as follows: Eighteen patients (pneumonia 13, purulent tonsillitis 1, acute bronchitis 1, cellulitis 1, urinary tract infection 2) were treated intravenously with daily 27.4-100.2 mg/kg of T-1982 in 3-4 divided dose for 3-6.7 days. The overall efficacy rate was 94.4%. No adverse reactions were observed. Abnormal laboratory data noted were liver dysfunction in 1 case (4.8%), eosinophilia in 2 cases (9.5%), and anemia in 1 case (4.8%).
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000627:therapeutic use*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D011014:Pneumonia / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; C035978:cefbuperazone